Health and Fitness Health and Fitness
Tue, February 24, 2009
Mon, February 23, 2009
[ Mon, Feb 23rd 2009 ] - Market Wire
Amedisys to Host Investor Day
Sun, February 22, 2009
Fri, February 20, 2009
Thu, February 19, 2009
[ Thu, Feb 19th 2009 ] - Market Wire
Enzon Reports 2008 Results
Wed, February 18, 2009
Tue, February 17, 2009
Mon, February 16, 2009
Fri, February 13, 2009
Thu, February 12, 2009
Wed, February 11, 2009
Tue, February 10, 2009
Mon, February 9, 2009
Sun, February 8, 2009
Fri, February 6, 2009

Schaeffer's Street Stories: Cephalon Inc. Struggles with Staunch Technical Resistance


//health-fitness.news-articles.net/content/2009/ .. struggles-with-staunch-technical-resistance.html
Published in Health and Fitness on Friday, February 13th 2009 at 9:02 GMT, Last Modified on 2009-02-13 09:02:41 by Market Wire   Print publication without navigation


CINCINNATI--([ BUSINESS WIRE ])--Pharmaceutical giant Cephalon Inc. (NASDAQ: CEPH) slipped into the earnings spotlight after the close last night to report that its fourth-quarter profit dropped, due to a large charge for ending a partnership on a drug to help alcoholics, and higher research and development costs. For the quarter, earnings rolled in at $1.46 per share, excluding items, beating the consensus estimate by 10 cents.

CEPH posted a net profit of $11.6 million, or 15 cents per share, compared with a net profit of $41.8 million, or 53 cents a share, a year ago. Revenue for the quarter rose 20% to $540.1 million, fueled by a 28% rise in sales of Provigil, for the sleep disorder narcolepsy, to $281.2 million. Analysts had predicted revenue of $525.9 million.

To continue reading this article, click here: [ http://www.schaeffersresearch.com/commentary/content/cephalon+inc+struggles+with+staunch+technical+resistance/observations.aspx?click=home&ID=91170&source=businesswire ]


Publication Contributing Sources